Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis

Next Previous
Search
Trial Profile

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anifrolumab (Primary) ; Glucocorticoids; Mycophenolate mofetil
  • Indications Lupus nephritis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms TULIP-LN; TULIP-LN1
  • Sponsors AstraZeneca

    • Most Recent Events

    • 15 Jun 2024 Results assessing the impact of anifrolumab treatment on the urinary biomarker of renal inflammation, CD163, compared with placebo presented at the 25th Annual Congress of the European League Against Rheumatism
    • 15 Nov 2023 Results (n=117) assessing untargeted metabolomics profiling on urine samples from the phase 2 trial to identify markers associated with LN disease activity that were modulated by anifrolumab, presented at the ACR Convergence 2023.
    • 03 Jun 2023 Results assessing unbiased metabolomic serum profiling to determine novel biomarkers of treatment response and provide insights into the mechanism of action of anifrolumab presented at the 24th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top